Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad

Rearranged during transfection (RET) fusions have been newly identified in approximately 1% of patients with primary lung tumors. However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of thoracic oncology 2012-12, Vol.7 (12), p.1872-1876
Hauptverfasser: Matsubara, Daisuke, Kanai, Yoshihiko, Ishikawa, Shumpei, Ohara, Shiori, Yoshimoto, Taichiro, Sakatani, Takashi, Oguni, Sachiko, Tamura, Tomoko, Kataoka, Hiroaki, Endo, Shunsuke, Murakami, Yoshinori, Aburatani, Hiroyuki, Fukayama, Masashi, Niki, Toshiro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1876
container_issue 12
container_start_page 1872
container_title Journal of thoracic oncology
container_volume 7
creator Matsubara, Daisuke
Kanai, Yoshihiko
Ishikawa, Shumpei
Ohara, Shiori
Yoshimoto, Taichiro
Sakatani, Takashi
Oguni, Sachiko
Tamura, Tomoko
Kataoka, Hiroaki
Endo, Shunsuke
Murakami, Yoshinori
Aburatani, Hiroyuki
Fukayama, Masashi
Niki, Toshiro
description Rearranged during transfection (RET) fusions have been newly identified in approximately 1% of patients with primary lung tumors. However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on lung tumors with endogenous RET fusion has not yet been studied. In this study, we report identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line LC-2/ad. LC-2/ad showed distinctive sensitivity to the RET inhibitor, vandetanib, among 39 non–small lung cancer cell lines. The xenograft tumor of LC-2/ad showed cribriform acinar structures, a morphologic feature of primary RET fusion–positive lung adenocarcinomas. LC-2/ad cells could provide useful resources to analyze molecular functions of RET-fusion protein and its response to RET inhibitors.
doi_str_mv 10.1097/JTO.0b013e3182721ed1
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273246879</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1556086415331737</els_id><sourcerecordid>1273246879</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5190-3cbaf860017df7a64cde0f42c9ab67d713e2350c927339bc3692bdcd5b465d4a3</originalsourceid><addsrcrecordid>eNp9kE1v1DAQQC1ERUvhHyDkIwfSjj-TXJCq0NJWkSpVC1fLsSesIYlLnFDx7_FqF5A49DCakTVvZvwIecPgjEFdnt9u7s6gAyZQsIqXnKFnz8gJU0oXTFTw_FBDpeUxeZnSNwCpQFYvyDEXTEml4YR8ufE4LaEPzi4hTjT2tGk-Nrq4v9zQqzXt3sJEly3S63W0E23X6Su9yFB0dnZhiqOlDQ4DbcOE72nbFPzc-lfkqLdDwteHfEo-X11umuuivft001y0hVOshkK4zvaVBmCl70urpfMIveSutp0ufZk_x4UCV_NSiLpzQte8886rTmrlpRWn5N1-7sMcf6yYFjOG5PI5dsK4JsMyyKWuyjq3yn2rm2NKM_bmYQ6jnX8ZBmZn1GSj5n-jGXt72LB2I_q_0B-F_-Y-xmHBOX0f1keczRbtsGwNMC5FVcuC54pxAChy8B32YY9h1vMzZCK5gJNDH2Z0i_ExPH3Yb5jbk7c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273246879</pqid></control><display><type>article</type><title>Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Matsubara, Daisuke ; Kanai, Yoshihiko ; Ishikawa, Shumpei ; Ohara, Shiori ; Yoshimoto, Taichiro ; Sakatani, Takashi ; Oguni, Sachiko ; Tamura, Tomoko ; Kataoka, Hiroaki ; Endo, Shunsuke ; Murakami, Yoshinori ; Aburatani, Hiroyuki ; Fukayama, Masashi ; Niki, Toshiro</creator><creatorcontrib>Matsubara, Daisuke ; Kanai, Yoshihiko ; Ishikawa, Shumpei ; Ohara, Shiori ; Yoshimoto, Taichiro ; Sakatani, Takashi ; Oguni, Sachiko ; Tamura, Tomoko ; Kataoka, Hiroaki ; Endo, Shunsuke ; Murakami, Yoshinori ; Aburatani, Hiroyuki ; Fukayama, Masashi ; Niki, Toshiro</creatorcontrib><description>Rearranged during transfection (RET) fusions have been newly identified in approximately 1% of patients with primary lung tumors. However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on lung tumors with endogenous RET fusion has not yet been studied. In this study, we report identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line LC-2/ad. LC-2/ad showed distinctive sensitivity to the RET inhibitor, vandetanib, among 39 non–small lung cancer cell lines. The xenograft tumor of LC-2/ad showed cribriform acinar structures, a morphologic feature of primary RET fusion–positive lung adenocarcinomas. LC-2/ad cells could provide useful resources to analyze molecular functions of RET-fusion protein and its response to RET inhibitors.</description><identifier>ISSN: 1556-0864</identifier><identifier>EISSN: 1556-1380</identifier><identifier>DOI: 10.1097/JTO.0b013e3182721ed1</identifier><identifier>PMID: 23154560</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - genetics ; Adenocarcinoma - pathology ; Animals ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Blotting, Western ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Cell line ; Cell Proliferation - drug effects ; Cytoskeletal Proteins - genetics ; Female ; Gefitinib ; Humans ; Immunoenzyme Techniques ; Lung adenocarcinoma ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Oncogene Proteins, Fusion - genetics ; Phosphorylation - drug effects ; Piperidines - administration &amp; dosage ; Proto-Oncogene Proteins c-ret - genetics ; Quinazolines - administration &amp; dosage ; Real-Time Polymerase Chain Reaction ; RET fusion ; Reverse Transcriptase Polymerase Chain Reaction ; RNA, Messenger - genetics ; Transplantation, Heterologous ; Tumor Cells, Cultured ; Vandetanib</subject><ispartof>Journal of thoracic oncology, 2012-12, Vol.7 (12), p.1872-1876</ispartof><rights>2012 International Association for the Study of Lung Cancer</rights><rights>2012International Association for the Study of Lung Cancer</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5190-3cbaf860017df7a64cde0f42c9ab67d713e2350c927339bc3692bdcd5b465d4a3</citedby><cites>FETCH-LOGICAL-c5190-3cbaf860017df7a64cde0f42c9ab67d713e2350c927339bc3692bdcd5b465d4a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23154560$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsubara, Daisuke</creatorcontrib><creatorcontrib>Kanai, Yoshihiko</creatorcontrib><creatorcontrib>Ishikawa, Shumpei</creatorcontrib><creatorcontrib>Ohara, Shiori</creatorcontrib><creatorcontrib>Yoshimoto, Taichiro</creatorcontrib><creatorcontrib>Sakatani, Takashi</creatorcontrib><creatorcontrib>Oguni, Sachiko</creatorcontrib><creatorcontrib>Tamura, Tomoko</creatorcontrib><creatorcontrib>Kataoka, Hiroaki</creatorcontrib><creatorcontrib>Endo, Shunsuke</creatorcontrib><creatorcontrib>Murakami, Yoshinori</creatorcontrib><creatorcontrib>Aburatani, Hiroyuki</creatorcontrib><creatorcontrib>Fukayama, Masashi</creatorcontrib><creatorcontrib>Niki, Toshiro</creatorcontrib><title>Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad</title><title>Journal of thoracic oncology</title><addtitle>J Thorac Oncol</addtitle><description>Rearranged during transfection (RET) fusions have been newly identified in approximately 1% of patients with primary lung tumors. However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on lung tumors with endogenous RET fusion has not yet been studied. In this study, we report identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line LC-2/ad. LC-2/ad showed distinctive sensitivity to the RET inhibitor, vandetanib, among 39 non–small lung cancer cell lines. The xenograft tumor of LC-2/ad showed cribriform acinar structures, a morphologic feature of primary RET fusion–positive lung adenocarcinomas. LC-2/ad cells could provide useful resources to analyze molecular functions of RET-fusion protein and its response to RET inhibitors.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - pathology</subject><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Blotting, Western</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Cell line</subject><subject>Cell Proliferation - drug effects</subject><subject>Cytoskeletal Proteins - genetics</subject><subject>Female</subject><subject>Gefitinib</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Lung adenocarcinoma</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Mice</subject><subject>Mice, Inbred NOD</subject><subject>Mice, SCID</subject><subject>Oncogene Proteins, Fusion - genetics</subject><subject>Phosphorylation - drug effects</subject><subject>Piperidines - administration &amp; dosage</subject><subject>Proto-Oncogene Proteins c-ret - genetics</subject><subject>Quinazolines - administration &amp; dosage</subject><subject>Real-Time Polymerase Chain Reaction</subject><subject>RET fusion</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>RNA, Messenger - genetics</subject><subject>Transplantation, Heterologous</subject><subject>Tumor Cells, Cultured</subject><subject>Vandetanib</subject><issn>1556-0864</issn><issn>1556-1380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQQC1ERUvhHyDkIwfSjj-TXJCq0NJWkSpVC1fLsSesIYlLnFDx7_FqF5A49DCakTVvZvwIecPgjEFdnt9u7s6gAyZQsIqXnKFnz8gJU0oXTFTw_FBDpeUxeZnSNwCpQFYvyDEXTEml4YR8ufE4LaEPzi4hTjT2tGk-Nrq4v9zQqzXt3sJEly3S63W0E23X6Su9yFB0dnZhiqOlDQ4DbcOE72nbFPzc-lfkqLdDwteHfEo-X11umuuivft001y0hVOshkK4zvaVBmCl70urpfMIveSutp0ufZk_x4UCV_NSiLpzQte8886rTmrlpRWn5N1-7sMcf6yYFjOG5PI5dsK4JsMyyKWuyjq3yn2rm2NKM_bmYQ6jnX8ZBmZn1GSj5n-jGXt72LB2I_q_0B-F_-Y-xmHBOX0f1keczRbtsGwNMC5FVcuC54pxAChy8B32YY9h1vMzZCK5gJNDH2Z0i_ExPH3Yb5jbk7c</recordid><startdate>201212</startdate><enddate>201212</enddate><creator>Matsubara, Daisuke</creator><creator>Kanai, Yoshihiko</creator><creator>Ishikawa, Shumpei</creator><creator>Ohara, Shiori</creator><creator>Yoshimoto, Taichiro</creator><creator>Sakatani, Takashi</creator><creator>Oguni, Sachiko</creator><creator>Tamura, Tomoko</creator><creator>Kataoka, Hiroaki</creator><creator>Endo, Shunsuke</creator><creator>Murakami, Yoshinori</creator><creator>Aburatani, Hiroyuki</creator><creator>Fukayama, Masashi</creator><creator>Niki, Toshiro</creator><general>Elsevier Inc</general><general>International Association for the Study of Lung Cancer</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201212</creationdate><title>Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad</title><author>Matsubara, Daisuke ; Kanai, Yoshihiko ; Ishikawa, Shumpei ; Ohara, Shiori ; Yoshimoto, Taichiro ; Sakatani, Takashi ; Oguni, Sachiko ; Tamura, Tomoko ; Kataoka, Hiroaki ; Endo, Shunsuke ; Murakami, Yoshinori ; Aburatani, Hiroyuki ; Fukayama, Masashi ; Niki, Toshiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5190-3cbaf860017df7a64cde0f42c9ab67d713e2350c927339bc3692bdcd5b465d4a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - pathology</topic><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Blotting, Western</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Cell line</topic><topic>Cell Proliferation - drug effects</topic><topic>Cytoskeletal Proteins - genetics</topic><topic>Female</topic><topic>Gefitinib</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Lung adenocarcinoma</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Mice</topic><topic>Mice, Inbred NOD</topic><topic>Mice, SCID</topic><topic>Oncogene Proteins, Fusion - genetics</topic><topic>Phosphorylation - drug effects</topic><topic>Piperidines - administration &amp; dosage</topic><topic>Proto-Oncogene Proteins c-ret - genetics</topic><topic>Quinazolines - administration &amp; dosage</topic><topic>Real-Time Polymerase Chain Reaction</topic><topic>RET fusion</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>RNA, Messenger - genetics</topic><topic>Transplantation, Heterologous</topic><topic>Tumor Cells, Cultured</topic><topic>Vandetanib</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsubara, Daisuke</creatorcontrib><creatorcontrib>Kanai, Yoshihiko</creatorcontrib><creatorcontrib>Ishikawa, Shumpei</creatorcontrib><creatorcontrib>Ohara, Shiori</creatorcontrib><creatorcontrib>Yoshimoto, Taichiro</creatorcontrib><creatorcontrib>Sakatani, Takashi</creatorcontrib><creatorcontrib>Oguni, Sachiko</creatorcontrib><creatorcontrib>Tamura, Tomoko</creatorcontrib><creatorcontrib>Kataoka, Hiroaki</creatorcontrib><creatorcontrib>Endo, Shunsuke</creatorcontrib><creatorcontrib>Murakami, Yoshinori</creatorcontrib><creatorcontrib>Aburatani, Hiroyuki</creatorcontrib><creatorcontrib>Fukayama, Masashi</creatorcontrib><creatorcontrib>Niki, Toshiro</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thoracic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsubara, Daisuke</au><au>Kanai, Yoshihiko</au><au>Ishikawa, Shumpei</au><au>Ohara, Shiori</au><au>Yoshimoto, Taichiro</au><au>Sakatani, Takashi</au><au>Oguni, Sachiko</au><au>Tamura, Tomoko</au><au>Kataoka, Hiroaki</au><au>Endo, Shunsuke</au><au>Murakami, Yoshinori</au><au>Aburatani, Hiroyuki</au><au>Fukayama, Masashi</au><au>Niki, Toshiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad</atitle><jtitle>Journal of thoracic oncology</jtitle><addtitle>J Thorac Oncol</addtitle><date>2012-12</date><risdate>2012</risdate><volume>7</volume><issue>12</issue><spage>1872</spage><epage>1876</epage><pages>1872-1876</pages><issn>1556-0864</issn><eissn>1556-1380</eissn><abstract>Rearranged during transfection (RET) fusions have been newly identified in approximately 1% of patients with primary lung tumors. However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on lung tumors with endogenous RET fusion has not yet been studied. In this study, we report identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line LC-2/ad. LC-2/ad showed distinctive sensitivity to the RET inhibitor, vandetanib, among 39 non–small lung cancer cell lines. The xenograft tumor of LC-2/ad showed cribriform acinar structures, a morphologic feature of primary RET fusion–positive lung adenocarcinomas. LC-2/ad cells could provide useful resources to analyze molecular functions of RET-fusion protein and its response to RET inhibitors.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23154560</pmid><doi>10.1097/JTO.0b013e3182721ed1</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1556-0864
ispartof Journal of thoracic oncology, 2012-12, Vol.7 (12), p.1872-1876
issn 1556-0864
1556-1380
language eng
recordid cdi_proquest_miscellaneous_1273246879
source MEDLINE; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adenocarcinoma - drug therapy
Adenocarcinoma - genetics
Adenocarcinoma - pathology
Animals
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Blotting, Western
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - pathology
Cell line
Cell Proliferation - drug effects
Cytoskeletal Proteins - genetics
Female
Gefitinib
Humans
Immunoenzyme Techniques
Lung adenocarcinoma
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Mice
Mice, Inbred NOD
Mice, SCID
Oncogene Proteins, Fusion - genetics
Phosphorylation - drug effects
Piperidines - administration & dosage
Proto-Oncogene Proteins c-ret - genetics
Quinazolines - administration & dosage
Real-Time Polymerase Chain Reaction
RET fusion
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger - genetics
Transplantation, Heterologous
Tumor Cells, Cultured
Vandetanib
title Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T23%3A57%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identification%20of%20CCDC6-RET%20Fusion%20in%20the%20Human%20Lung%20Adenocarcinoma%20Cell%20Line,%20LC-2/ad&rft.jtitle=Journal%20of%20thoracic%20oncology&rft.au=Matsubara,%20Daisuke&rft.date=2012-12&rft.volume=7&rft.issue=12&rft.spage=1872&rft.epage=1876&rft.pages=1872-1876&rft.issn=1556-0864&rft.eissn=1556-1380&rft_id=info:doi/10.1097/JTO.0b013e3182721ed1&rft_dat=%3Cproquest_cross%3E1273246879%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273246879&rft_id=info:pmid/23154560&rft_els_id=S1556086415331737&rfr_iscdi=true